Kura Oncology, Inc. (KURA)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$39.1M
Cash & Equivalents
$85.9M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$1,016M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
ZIFTOMENIB
KOMZIFTI |
APPROVED | Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Lymphoblastic Leukemia, With KMT2A Rearrangements, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, With KMT2A Rearrangements, Acute Myeloid Leukemia, With NPM1 Mutations, Advanced Malignant Neoplasm, Advanced Solid Tumor, AML, AML With Mutated NPM1, Clear Cell Renal Cell Carcinoma (ccRCC), Colorectal Cancer (CRC), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Cell Tumors, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Tumor, Malignant, Hematologic Malignancy, HNSCC, HRAS Gene Mutation, HRAS Mutant Tumor, HRAS Mutations or Peripheral T Cell Lymphoma (PTCL), KMT2A-rearranged, KMT2Ar, Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoblastic Leukemia, Mixed Line |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase1 Readout | — |
| 2027-01-01 | Phase1 Readout | — |
| 2027-07-01 | Phase1 Readout | — |
Active Clinical Trials (9)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | PHASE3 | Recruiting | 1,300 |
| NCT05848687 | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | PHASE2 | Recruiting | 90 |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | PHASE2 | Active Not Recruiting | 263 |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | PHASE1 | Recruiting | 300 |
| NCT06397027 | A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Re... | PHASE1 | Recruiting | 22 |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,... | PHASE1 | Recruiting | 420 |
| NCT06001788 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | PHASE1 | Recruiting | 171 |
| NCT06448013 | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediat... | PHASE1 | Recruiting | 22 |
| NCT06655246 | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | PHASE1 | Recruiting | 157 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.